Influenza in long-term care facilities by Lansbury, Louise E. et al.
Lansbury, Louise E. and Brown, Caroline S. and 
Nguyen-Van-Tam, Jonathan S. (2017) Influenza in long-
term care facilities. Influenza and Other Respiratory 
Viruses . ISSN 1750-2659 (In Press) 
Access from the University of Nottingham repository: 
http://eprints.nottingham.ac.uk/44186/1/Lansbury_et_al-2017-
Influenza_and_Other_Respiratory_Viruses.pdf
Copyright and reuse: 
The Nottingham ePrints service makes this work by researchers of the University of 
Nottingham available open access under the following conditions.
This article is made available under the Creative Commons Attribution licence and may be 
reused according to the conditions of the licence.  For more details see: 
http://creativecommons.org/licenses/by/2.5/
A note on versions: 
The version presented here may differ from the published version or from the version of 
record. If you wish to cite this item you are advised to consult the publisher’s version. Please 
see the repository url above for details on accessing the published version and note that 
access may require a subscription.
For more information, please contact eprints@nottingham.ac.uk
A
cc
ep
te
d 
A
rt
ic
le
This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/irv.12464 
This article is protected by copyright. All rights reserved. 
DR. LOUISE ELIZABETH LANSBURY (Orcid ID : 0000-0002-6647-4618) 
 
Article type      : Expert Commentary 
 
Influenza in Long-Term Care Facilities 
 
Louise E Lansbury*, Health Protection and Influenza Research Group, Division of Epidemiology and 
Public Health, University of Nottingham, Clinical Sciences Building, City Hospital, Hucknall Road, 
Nottingham NG5 1PB, UK. Telephone +44 (0)115 8231251           
Louise.Lansbury@nottingham.ac.uk     
 
Caroline S Brown, Influenza & Other Respiratory Pathogens Programme, Division of Communicable 
Diseases and Health Security, WHO Regional Office for Europe, UN City, Marmorvej 51, 2100 
Copenhagen, Denmark 
 
Jonathan S Nguyen-Van-Tam, Health Protection and Influenza Research Group, Division of 
Epidemiology and Public Health, University of Nottingham, Clinical Sciences Building, City Hospital, 
Hucknall Road, Nottingham NG5 1PB, UK 
 
*Corresponding author 
 
Abstract 
Long-term care facility environments and the vulnerability of their residents provide a setting 
conducive to the rapid spread of influenza virus and other respiratory pathogens. Infections may be 
introduced by staff, visitors or new or transferred residents, and outbreaks of influenza in such 
settings can have devastating consequences for individuals, as well as placing extra strain on health 
services.  As the population ages over the coming decades, increased provision of such facilities 
seems likely. The need for robust infection prevention and control practices will therefore remain of 
paramount importance if the impact of outbreaks is to be minimised. In this review, we discuss the 
nature of the problem of influenza in long-term care facilities, and approaches to preventive and 
control measures, including vaccination of residents and staff, and the use of antiviral drugs for 
treatment and prophylaxis, based on currently available evidence.  
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Introduction 
The term ‘long-term care facility’ (LTCF) encompasses a diverse range of healthcare settings 
including nursing homes, rehabilitation centres, long-term care hospitals, psychiatric care facilities, 
and facilities for people with intellectual disabilities1. Although people of all ages may reside in these 
facilities, the majority of residents are elderly. With the population in Europe aged 85 years and 
above projected to rise from 14 million currently to 19 million by 2020 and to 40 million by 2050, 
and the expectation that more than 30% of European citizens will be aged over 60 years by 2050, the 
proportion of the population in countries at all levels of development which requires long-term care 
is only to set to increase dramatically over the coming decades2.  
Outbreaks of seasonal influenza in LTCFs are well recognised, as are the challenges of preventing and 
controlling influenza outbreaks in these settings. The development of universally applicable guidance 
on the prevention and control of influenza and other respiratory viruses in LTCFs is difficult due to 
the huge variation in the size of facilities, patient characteristics, the intensity of care provided and 
resources available. Although some countries have produced guidance on infection prevention and 
control for use specifically in LTCFs3-11, most have not. To help fill this gap, the WHO has recently 
published a best practice guidance document to support managers of LTCFs in the 53 WHO 
European Region Member States and which can be tailored according to national and local 
circumstances.12 (http://www.euro.who.int/__data/assets/pdf_file/0015/330225/LTCF-best-
practice-guidance.pdf?ua=1) 
In this review, we examine the impact of seasonal influenza in LTCFs, and approaches to the 
prevention and control of outbreaks, as outlined by the advice and evidence we provided in the 
WHO best practice document.    
 
The impact of influenza 
Persons residing in LTCFs present a population very susceptible to the acquisition and spread of 
infectious diseases and for whom the consequences of infection may be serious.  Nursing home 
residents are at greatest risk due to their overall frailty, close quarter living arrangements, shared 
caregivers, and opportunities for introduction of healthcare associated infections and the spread of 
pathogens to other facilities through resident transfers and the movement of staff and visitors in 
and out of the home 13, 14.  
Outbreaks of influenza caused by both influenza A and B viruses are well-documented in LTCFs, and 
may be explosive15, with high mortality, highlighting the need for early recognition and prompt 
initiation of control measures. Accurate measurement of the burden of influenza is heavily 
influenced by circulating types and subtypes of virus and may vary between communities and 
between institutions so studies that attempt to estimate this burden require temporal, geographical 
and institutional breadth16. Older studies, relying on culture-based detection techniques, may have 
underestimated total burden. A review of 206 published infectious outbreaks in elderly care facilities 
across 19 countries over 40 years identified 37 different pathogens, but influenza viruses caused the 
largest number of outbreaks (23%) 17.  In the 49 outbreaks caused by influenza, the median attack 
rate in residents was 33% (range 4 to 94%), and 23% (range 3-58%) among staff, with a median case-
fatality rate for residents of 6.5% (range 0 to 55%). Over three consecutive 9-year time periods 
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between 1980 and 2008, there was no observed decrease in attack rates or case-fatality rates; 
nevertheless, these data should be interpreted cautiously as antiviral use and the stringency of 
application of IPC practices has changed over time. 
Exposure to influenza in residents of LTCFs for the elderly increases their risk of respiratory-origin 
hospitalisation (Relative Risk (RR) 1.43 (95% CI 0.99-2.08), and particularly increases the risk of death 
due to a respiratory cause (RR 2.77 (95% CI 1.55 to 4.91) compared to unexposed residents, despite 
high levels of vaccination among the residents (93%)18.  
Bronchitis and pneumonia, either primary influenza pneumonia or secondary bacterial pneumonia, 
are the most common respiratory complications of influenza infection, but infection may also cause 
extrapulmonary cardiovascular, neurological and musculoskeletal manifestations. A retrospective 
cohort study of nursing home residents in 381 nursing homes across three seasons, estimated for 
the 63% of residents with comorbid conditions, influenza contributed to approximately 28 
hospitalisations,147 courses of antibiotics and 15 deaths per 1000 person-years annually; a higher 
burden than residents without comorbid conditions but in whom there were still 7 hospitalisations, 
99 excess antibiotic prescriptions and 6 deaths per 1000 residents annually.16   Increased age itself is 
a recognised risk factor for serious influenza infection. A systematic review evaluating populations at 
risk for severe influenza related illness found that for seasonal influenza (H3N2 or type B) there was 
raised risk of hospitalization (odds ratio (OR) 4.65, 95% confidence intervals (CI) 1.74 to 12.41) and 
risk of death (OR 2.95, 95% CI 1.53 to 5.70) among elderly people (>65 years) compared with non-
elderly people 19. Modelling studies suggest that the burden on the health services is particularly 
onerous for those aged 75 and above, with an estimated 36% of all influenza-attributable respiratory 
hospitalisations and 74% of all influenza-associated deaths occurring in this age group in the UK over 
13 seasons20, and accounting for 52% of total hospital bed occupancy and 69% of excess bed days 
occupancy in England over a similar number of seasons21.  
 
Epidemiology 
Outbreaks of influenza (and other respiratory virus pathogens) in LTCFs in the Northern hemisphere 
occur most commonly during the winter but may occur at any time of year, particularly in the 
autumn months usually due to circulation of influenza A(H3N2) and before seasonal vaccination 
campaigns have been fully implemented or when matching is poor; also in the spring when influenza 
B often peaks22 and when antibody titres may have declined in the vaccinated23, 24.   
Influenza virus replicates in the epithelium of the upper and lower respiratory tract, with infected 
hosts releasing virus into the environment during breathing, talking, coughing and sneezing, 
producing a spray of virus-containing particles ranging in size from 0.01-500μm25. Transmission of 
influenza may occur by 3 routes: droplet (larger-sized particles too large to be inhaled into the lungs 
and settle quickly to the ground or other surface within 2 meters of the source); aerosol or droplet 
nuclei (small particles < 5μm which can remain suspended in the air much longer and are potentially 
inhalable into the lower respiratory tract; and contact (transfer of infectious particles to the mucous 
membranes directly or indirectly through contaminated objects). The relative importance of each of 
these routes in influenza transmission is unclear and the contribution of aerosolised infectious 
droplet nuclei has been particularly contentious. 26-29 30, 31. However most influenza transmission is 
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short range and when it has occurred over longer distances, contact transmission has generally not 
been ruled out32. Transmission studies often do not control for confounders such as vaccination 
status, handwashing practice, supershedders, amount of coughing, ward layout, surface 
contamination and ventilation, 33and further studies which control for these are required in this 
area.. 
The incubation period of influenza is typically short, usually reported as ranging from 1 to 4 days,34 
with a serial interval (time between symptom onset in a secondary case and that of its primary case) 
of 2.2 to 3.5 days for influenza A and 3.4 to 4.9 days for influenza B 35. The relatively short incubation 
period and serial interval enables the virus to spread rapidly through communities, so mitigation 
measures such as isolation and transmission-based precautions should be instigated as soon as a 
case of suspected influenza is identified in order to minimise the risk of transmission to contacts. 
Viral shedding has generally been considered to be a proxy for influenza infectiousness 36-38, peaking 
1 to 3 days after symptom onset with most healthy volunteers clearing virus by day 6 to 734. 
However a recent study of household influenza transmission found at most only a weak association 
between viral load in nose and throat swabs and infectivity, possibly due to the weak correlation 
between virus concentration in exhaled breath and nose and throat samples, or due to the intensity 
of household transmission so that even those with low viral loads are still capable of infecting those 
around them39. Pre-symptomatic shedding may occur in up to one-third of cases 40-43 and prolonged 
viral shedding has been reported in children 42, 44, 45, in patients hospitalised with severe influenza 46, 
and in immunocompromised patients 47, in whom prolonged shedding may last weeks or even 
months 48, 49.  The transmission dynamics of influenza infections in residents of LTCFs have not been 
studied; age >65 years and the presence of major co-morbidities were associated with prolonged 
shedding of virus and higher viral load in a prospective observational study of hospitalised influenza 
patients46; these findings may raise the possibility of prolonged shedding in LTCF residents. 
Transmission of influenza from healthcare workers (HCWs) to hospital patients, including those in 
geriatric facilities, has been well documented using epidemiological linkage, nucleotide sequence 
analysis and contact tracking data 50-53and case reports of outbreaks of influenza-like illness in care 
facilities indicate that staff can transmit the virus to residents54, 55. A systematic review comparing 
the incidence of influenza in HCWs with other workers not working in a healthcare setting and taking 
vaccination status into account, found estimated incidence rates (IRs) for all influenza infections 
(defined as a ≥4-fold increase in antibody titre over the influenza season and including asymptomatic 
infections) of  18.7/100 population/season (95% CI 15.8 to 22.1) for unvaccinated HCWs and 6.5/100 
population/season (95% CI 4.6 to 9.0) for vaccinated HCWs, both higher than the IRs in unvaccinated 
and vaccinated other workers (5.4/100 population/season (95% CI 3.0 to 9.8) and 1.2 (95% CI 0.9 to 
1.7) respectively)56. However, no difference was observed between IRs for symptomatic infection 
confirmed serologically in HCWs compared to other workers; this overall lack of consistency in 
findings between overall and symptomatic infections indicates the need for cautious interpretation. 
The observed variability might be explained by HCWs being at higher risk of asymptomatic or sub-
clinical infection, indicating that HCWs may act as an infective pool to transmit influenza to frail 
elderly people. Furthermore, a study of HCWs in an acute hospital during a mild epidemic season, 
found that 23% had serological evidence of new influenza infection during the season, implying a 
potential transmission risk to patients since between 28% and 59% of infected workers had 
subclinical infections and continued to work 57. Although the role of asymptomatic people and those 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
with only mild symptoms in spreading influenza is uncertain, HCWs often continue to work despite 
having symptoms and may act as a source of infection to those in their care 58-60. Nursing home aides 
in particular have been shown in one Swedish study to be the occupational group at significantly 
greatest risk of continuing to work despite the feeling that, in the light of their perceived state of 
health, they should have taken sick leave 61. However, in reality the employment status of many LTCF 
staff is often precarious and taking unpaid sick leave may result in adverse economic consequences. 
 
Routine and Pre-outbreak Prevention Measures 
Planning, Training and Education 
LTCFs have a broad staff base and may include people with little or no formal healthcare training. 
Depending upon the type of facility and the nursing needs of the residents, services are provided by 
a range of staff including care assistants with few formal healthcare qualifications, registered nurses, 
domestic staff, catering and administrative staff, with additional ambulatory health services usually 
provided by external contractors such as general practitioners (GPs) and other healthcare 
professionals not directly affiliated to the facility. Managers of LTCFs have an important role in 
ensuring that all staff have ongoing training on the importance and practice of infection prevention 
and control (IPC), and that the facilities are available for IPC measures to be implemented to a 
satisfactory standard and with standard precautions being used at all times, regardless of the 
detection of a suspected outbreak. Written policies should be in place in every LTCF outlining: 
resident and staff influenza immunisation policy; a written outbreak management plan which 
includes outbreak recognition (definitions, thresholds for suspicion of an outbreak), identification of 
communication channels, operational measures including active surveillance, staff contingency 
plans, visitor restriction policies, and consideration of antiviral treatment and prophylaxis strategy; a 
policy for ill staff to remain off work; a policy for dealing with visitors with symptoms of an acute 
respiratory tract infection. 
During the Severe Acute Respiratory Syndrome outbreak, compliance with IPC measures was found 
to be associated with HCWs’ perception that the facilities in which they worked had clear IPC policies 
and protocols, and that the management had a positive attitude towards occupational health and 
safety and provided training in IPC practices62.  Managers in LTCFs therefore have a pivotal role in 
creating a strong institutional climate in which staff feel valued, with continuous accessibility to the 
training resources, clear IPC policies and supplies and facilities required to promote compliance with 
IPC practices. 
 
Vaccination of LTCF residents 
A WHO strategy and action plan for healthy ageing in Europe 2012-2020 recognised the benefit of 
proper vaccination strategies against infectious diseases, including influenza, both in older people 
and for health and social care workers in contact with them, and proposed priority interventions 
including national immunisation schedules, including for higher age groups, and the implementation 
of infectious disease control programmes in institutions63. Furthermore, a WHO position paper 
published in 2012 recommended that elderly persons >=65 years and people with specific chronic 
diseases should be considered for influenza vaccination.64  Vaccination coverage of the elderly varies 
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considerably between European countries with recent uptakes rates reported between 1% and 77.4 
and with only two countries (the Netherlands and the UK) achieving, or almost achieving, the 2010 
WHO target of 75% coverage in the elderly 65. For residents of LTCF, recent data available from only 
3 countries indicated vaccination coverage rates of 71% to 89%65. .  
Vaccination of residents remains an important public health tool to protect the elderly and those 
with underlying conditions, but there is uncertainty about how effective immunisation is at an 
individual level in LTCF residents. . A systematic review assessing the effectiveness of influenza 
vaccine in people 65 years or over, with separate analyses for those living in nursing homes and 
community dwelling older people 66, concluded that for elderly people living in closed communities 
vaccination may be slightly to moderately more effective than no vaccination at preventing 
influenza-like illness (24% (95% CI 12-34%)), pneumonia (47% (95% CI 34-57%)), hospitalisation (49% 
(19-68%)), overall mortality (60% (95% CI 23-79%) and mortality from influenza or pneumonia (54% 
(95% CI 37-67%)), although no significant protective effect against proven influenza was found. A 
later systematic review 67 also found that vaccination may have a small significant protective effect 
against pneumonia (37% (95% CI 18-53%)) and mortality from influenza and pneumonia (34% (95% 
CI 10-53%)), in institutionalised older adults ≥60 years; also a trend towards protection against 
influenza like illness (21% (95% CI -3-39%)). The authors did not address the effectiveness of 
vaccination against all-cause mortality and, due to an insufficient number of studies, were unable to 
perform meta-analyses for laboratory-confirmed influenza or hospitalisation. The quality of the 
evidence is very weak in both reviews and does not definitively answer the uncertainty regarding the 
effectiveness of influenza vaccination in older people living in LTCFs. In particular, selection bias may 
occur by targeting the frail for immunization; conversely people who are  particularly frail or close to 
death may not receive vaccine resulting in overestimation of the effectiveness of vaccine on 
mortality (healthy recipient effect)68, 69. Although there is some indirect evidence of influenza vaccine 
effectiveness (IVE)against hospitalisation, pneumonia and death from studies which have controlled 
for multiple confounders and compared summer and winter mortality in vaccinated and 
unvaccinated elderly people70, 71, accurate proof of IVE requires adequately powered studies using 
laboratory-confirmed outcomes, in which confounders are controlled for and which 
comprehensively monitor morbidity and mortality.72 
 
Vaccination of LTCF staff 
Infection in HCWs affects not only themselves and their immediate family but may further inhibit 
efforts to control an outbreak if staff shortages result in remaining staff having to care for both 
affected and unaffected residents 73. On this basis HCWs are recognised as a priority group for 
vaccination and are generally recommended to receive it64, 74.  
High rates of staff vaccination in LTCFs have been demonstrated in several studies to decrease the 
risk of all-cause mortality and ILI in frail elderly residents, with lowest rates when both HCWs and 
patients had high vaccine coverage rates75-79. This has been somewhat refuted by a systematic 
review of 4 cluster-randomised controlled trials (RCTs) and one cohort study which suggested that 
offering vaccination to HCW caring for people aged over 60 in LTCFs may have little or no effect on 
laboratory-confirmed influenza (LCI) (Risk difference (RD) 0 (95% CI -0.03-0.03) and respiratory-
related hospitalisation in residents (RD 0 (95% CI -0.02-0.02), although there may be a small 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
decrease in lower respiratory infections from 6% to 4% in homes where HCW-vaccination is offered. 
(RD -0.02 (95% CI -0.04 to 0.01) 80. The effects on deaths due to LRTI and all-cause mortality were not 
evaluated by meta-analysis, but reductions in all-cause mortality were noted in the individual studies 
(ORs ranging from 0.56 (95% CI 0.4-0.8) to 0.80 (95% CI 0.67 to 0.97))75-77, 79. The authors called for 
high quality RCTs to address methodological flaws they identified in the included studies, and to test 
the effectiveness of co-interventions such as handwashing and face-mask use in combination with 
HCW vaccination. Another systematic review 81 found a significant reduction in ILI and all-cause 
mortality in residents associated with vaccination of HCWs (42% and 29% reductions respectively), 
but no significant reductions for laboratory-confirmed influenza or all-cause hospitalisations.   
Overall the authors rated the quality of evidence as very low to moderate for the different 
outcomes, and concluded that HCW influenza vaccination can enhance patient safety. Protective 
effects of HCW vaccination against non-specific outcomes may be an indication of unaccounted 
cluster biases, such as differences in handwashing or other IPC precautions and warrants further 
investigation82. Evidence from observational and modelling studies suggests a likely proportionate 
effect of HCW vaccination coverage on patient protection, although no clear threshold for HCW 
vaccine uptake above which the protective effect on residents increases substantially has been 
established83-87.  
Inactivated trivalent vaccines have been found to have a protective effect against proven influenza 
in healthy adults (overall protective effect in vaccine matched and poorly-matched seasons 62% 
(95% CI 56-67%)88. A systematic review specifically addressing the effectiveness of seasonal influenza 
vaccination in HCWs found just one study reporting laboratory-confirmed influenza in this group 
with a reported IVE of 88% (95% CI 59% to 96%, p=0.0005) in this group89.  
Although the currently available evidence may be weak for HCW vaccination to protect the frail and 
elderly, there is also generally no evidence against it. Therefore it remains a biologically plausible 
intervention to provide individual protection to the HCW, act as a barrier against spread of infection 
and to help reduce the risk associated with influenza infection and prevent staff absenteeism. 
However, poor vaccine uptake by HCWs has been well-documented. In Europe, coverage of HCWs 
(including those working in LTCFs) varies between countries and is generally much lower than for 
other vaccination targeted groups, ranging from 9.5% to 75% with a median vaccination coverage 
rate of 28.6% 65. In the US, vaccination rates of 50-70% have been reported for LTCF workers,78 90, 91 
with coverage consistently lower than among staff working in hospital settings91. Reasons given for 
declining vaccination include fear of side effects, lack of concern or perception of risk, doubts about 
vaccine efficacy, lack of availability or inconvenient delivery of vaccine, avoidance of medications 
and dislike of injections92. . Although mandatory vaccination is effective if it can be implemented,93 it 
is not  legally enforceable in all countries and settings, and infection rates after the implementation 
of mandatory vaccination have not been studied. The United States Department of Health and 
Human Services advocates a 90% HCW vaccination rate by 2020 but as yet there have been no RCTs 
of transmission with very high HCW vaccination rates.33 Data suggest that other interventions such 
as easier access to vaccine, educational activities, reminders and organisational changes can increase 
uptake in proportion to the number of interventional components, although most studies have only 
evaluated their effect on a short-term basis whereas long-term intervention programmes will be 
necessary to demonstrate a sustainable effect on uptake94. To address low uptake of seasonal 
influenza vaccination in priority target groups, a project called TIP FLU was initiated in 2013 by the 
WHO Influenza and other Respiratory Pathogens programme. Adapted from the Tailoring 
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Immunization Programmes (TIP) approach, it is based on social and behavioural change models and 
provides tools to identify priority populations, determine barriers and enablers to vaccination, and 
to implement evidence –based interventions. A guide and case study of the application of TIP FLU in 
Montenegro have been published to assist policy-makers and programme managers to increase 
vaccine uptake among HCWs95, 96.   
 
Early recognition of influenza in LTCFs 
Diagnosis in residents 
Early recognition of influenza in residents of LTCFs may be problematic due to non-specific 
symptoms and the possibility of atypical presentation and lack of fever in the elderly with 
influenza97, 98. Influenza may present as sudden, unexplained deterioration in physical or mental 
ability or exacerbation of an underlying condition with no other known cause15.   The use of 
surveillance case definitions for ILI in these populations may therefore miss cases, especially if they 
present without fever. Furthermore, other underlying conditions may impair residents’ abilities to 
verbalise their symptoms. This may impede the early implementation of control and treatment 
strategies99. The precise definition of influenza-like illness may vary from country to country; the 
WHO global surveillance case definition of ILI is an acute respiratory infection with measured fever 
≥38oC and cough and onset within the last 10 days100 whereas that of the Centers for Disease Control 
and Prevention (CDC) and European Centre for Disease Prevention and Control (ECDC) definition  is 
sudden onset of symptoms and at least one of four systematic symptoms (fever or feverishness, 
malaise, headache, myalgia) and at least one of three respiratory symptoms (cough, sore throat, 
shortness of breath)3, 101.  
 
To confirm an outbreak, reverse-transcriptase polymerase chain reaction or viral culture are the 
preferred methods of laboratory testing. Rapid point-of-care diagnostic tests can produce a result 
within 30 minutes but have lower sensitivity (median 70-75%)102 and there may be variability 
between different age groups and influenza subtypes103 although they may still be useful in outbreak 
situations, for example for rapid identification of influenza infection where timely access to more 
sensitive laboratory testing is unavailable or delayed. However, clinical judgement is required to 
interpret negative rapid test results for individual patients during an outbreak and negative rapid 
test results may not justify delaying the instigation of outbreak control measures if there is clinical 
and epidemiological suspicion.  
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Outbreak Control Measures 
Outbreak definitions vary between countries and are frequently based on the number of cases in a 
unit during a specified period of time. Although influenza may cause sporadic infection in LTCFs, 
given the vulnerability of the population and the propensity to spread rapidly, it is wise to have a low 
threshold for declaring an outbreak and commencing control measures, ideally before virological 
confirmation. One case may be indicative of incubating infection in exposed persons so these should 
be actively sought through daily surveillance of temperature and symptoms in all residents and staff.  
 
Infection prevention and control strategies in health-care facilities are commonly based on early 
recognition and controlling the source of the pathogen, administrative controls, environmental 
hygiene and engineering controls, and the use of personal protective equipment (PPE). In addition to 
Key Points 1: 
 LTCFs are susceptible to seasonal influenza outbreaks, which may be explosive and with 
high attack rates in residents. 
 Written IPC policies, vaccination policies for residents and staff, provision of ongoing 
staff IPC training and the facilities required to promote compliance with IPC practices 
should be in place throughout the year. 
 Although influenza vaccine efficacy is lower in the elderly and in the presence of co-
morbidities compared to healthy younger adults, vaccination of LTCF residents remains a 
major public health tool and is recommended. 
 Vaccination of LTCF staff is recommended and should be encouraged. Although evidence 
for a protective effect of HCW vaccination to protect the frail and elderly is weak, HCW 
vaccination can help to protect themselves, maintain the workforce during an outbreak, 
and act as a barrier to transmission of infection to the vulnerable. 
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standard IPC precautions, which are routine measures that should be practiced at all times by all 
staff and with all residents104, contact and droplet transmission based precautions  should be 
implemented as required when residents are suspected to be infected. 
The use of hygiene measures, such as hand hygiene, respiratory etiquette and appropriate use of 
personal protective equipment may reduce the transmission of respiratory viruses105-107 and are 
central to IPC programmes in LTCFs. Compliance with these measures may be an issue and there is 
currently a paucity of directly-observed studies of handwashing and mask-wearing.33 There is some 
evidence that the wearing of a surgical face mask by an infected person decreases their 
infectiousness to others108, 109 and may be considered for infected LTCF residents, particularly if they 
have to be moved outside their own room or cohort area; although in reality this measure may not 
be tolerated by some individuals. Residents sharing a room with an influenza-infected roommate 
have 3 times the risk of acquiring infection than those in single rooms110. Although there is little 
convincing evidence that social distancing and isolation are effective in reducing transmission105, 107, 
isolation of infected residents in single-occupancy rooms and limitation of social activities minimises 
transmission opportunities, although this may not be practical in many LTCFs with limited 
accommodation types, in which case cohorting infected residents together,(with separate cohorts of 
confirmed cases and those with the same suspected diagnosis on the basis of epidemiological and 
clinical information if possible) is an alternative to isolation. A balance may need striking between 
the strict enforcement of social isolation and visitor restrictions and psychological welfare in 
vulnerable populations. Other measures to control transmission will include closure of the facility to 
new admissions based on risk assessment, limitation of visitors, cohorting staff to avoid cross-over of 
care for infected and asymptomatic residents,  excluding staff with ILI symptoms, rostering 
vaccinated staff to care for infected residents, and preventing unvaccinated staff from working in 
other healthcare facilities during the outbreak. As influenza virus has been shown to survive on 
hands and inanimate surfaces from a few hours for up to several days111, regular and thorough hand 
hygiene and enhanced environmental cleaning may reduce contact transmission, and there is 
evidence that even simple, readily available, easy to handle products such as 1% bleach and 
detergents like 0.01% washing-up liquid are effective in killing influenza virus depending upon the 
material and situation and can be used even in low-resource settings112. 
 
Antiviral treatment 
Early recognition of an influenza outbreak in a LTCF can facilitate timely antiviral treatment and 
prophylaxis in order to end the outbreak and thus avoid influenza-related complications in exposed 
residents. The neuraminidase inhibitors (NAIs) oseltamivir and zanamivir are currently authorised for 
the treatment and prophylaxis of influenza in Europe and the United States. However, their 
effectiveness has been subject to much debate113 and many clinicians have felt confused about when 
to use them appropriately. 
A modest but significant reduction in time to first alleviation of symptoms has been consistently 
shown in meta-analyses of RCTs of previously healthy people, representing a 10 to 15% reduction in 
overall duration of symptoms in those treated with an NAI compared with those receiving placebo 
114 115 116, with similar reductions noted from analysis of observational studies117. This effect appears 
to be somewhat attenuated in the elderly115, 118. In general there is a lack of credible evidence from 
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RCTs that NAIs reduce the risk of hospitalisation and pneumonia114, 115, 118, although a significant 
reduction was seen in hospitalisation in the influenza-confirmed intention-to-treat population in one 
analysis ((RR 0.37 (95% CI 0.17 to 0.81))115, and reduced rates of lower respiratory tract 
complications were seen in 2 meta-analyses (RR 0.56 (95% CI 0.42 to 0.75)115 and 0.55 (95% CI 0.33 
to 0.90))114. However RCTs are generally underpowered to evaluate the effects of treatment on 
complications due to the rarity of such events and lack of precise outcome definition in many trials 
makes comparison of findings difficult. Meta-analysis of observational studies indicated a potential 
effect of oseltamivir in reducing hospitalisation in the general population (all ages) compared with 
no antiviral (OR 0.75 (95% CI 0.66 to 0.89)), but no significant effect was found for inhaled zanamivir 
(OR 0.66 (95% CI 0.37 to 1.18)) 117. Individual patient data meta-analysis from 29,234 people of all 
ages hospitalised with 2009 H1N1 pandemic influenza  showed that deaths were reduced when 
treated with NAIs within 48 hours of onset (OR 0.81 (95% CI 0.70 to 0.93), supporting the use of 
early NAI treatment in those who require hospitalisation 119.  A reduction in mortality risk for 
patients receiving oseltamivir compared to those not given antivirals was also noted  in a meta-
analysis of 3 observational studies (OR 0.23 (95% CI 0.13 to 0.43) but the quality of evidence was 
low, and related only to oseltamivir.117  
Uncertainties remain about the effectiveness of treatment in high-risk populations such as LTCF 
residents as much of the available evidence relates to previously healthy younger adults. However, 
given the high-risk of severe complications and deaths among the elderly from influenza virus 
infection, where influenza antivirals are available, treatment of symptomatic LTCF residents is 
generally recommended to be started immediately3, 120. 
 
Antiviral prophylaxis 
Prophylaxis with antivirals is intended to prevent transmission of influenza virus to people who are 
not exhibiting ILI but who have or may have been exposed. There is a paucity of evidence from 
recent studies to inform a single approach for antiviral prophylaxis use in LTCFs, so decisions should 
be based on clinical judgement and outbreak severity121. Prophylaxis with oseltamivir or zanamivir 
was shown to be more effective than placebo at preventing symptomatic influenza in individuals in 
the community (oseltamivir RR 0.45 (95% CI 0.30 to 0.67); zanamivir (RR 0.39 (95% CI 0.22 to 0.70)) 
and in household contacts (oseltamivir RR 0.20 (95% CI 0.09 to 0.44); zanamivir RR 0.33 (95% CI 0.18 
to 0.58)) in a recent meta-analysis of RCTs114. A reduced risk of LCI with oseltamivir and zanamivir 
prophylaxis was found in a further systematic review which also included data from observational 
studies, for both individuals (oseltamivir OR 0.11 (95% CI 0.06 to 0.20); zanamivir OR 0.23 (95% CI 
0.16 to 0.35)) and households (oseltamivir OR 0.23 (95% CI 0.09 to 0.59); zanamivir OR 0.18 (95% CI 
0.10 to 0.31))122. However, direct evidence of effectiveness in reducing symptomatic influenza in the 
frail elderly living in institutions is sparse; a non-significant protective trend with post-exposure 
zanamivir prophylaxis has been shown in one study (RR 0.08 (95% CI 0.01 to 0.63))123 but data for 
the effectiveness of post-exposure oseltamivir in this setting are lacking124.  Other studies have seen 
a non-significant effect of post–exposure prophylaxis and seasonal prophylaxis with zanamivir 124, 125.  
Prophylaxis for all residents in LTCFs experiencing an outbreak, regardless of vaccination status is 
recommended by the United States Centers for Disease Control and Prevention (CDC)3; the 
European Centre for Disease Prevention and Control (ECDC) expert opinion on the use of antivirals 
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for prophylaxis recommends consideration of antiviral prophylaxis for residents of LTCFs, especially 
for those who are unvaccinated or immunocompromised who do not respond to vaccination126. This 
may be particularly important during years when IVE is expected to be low due to vaccine strain 
mismatch. But the relatively low effectiveness of influenza vaccine in the elderly population even in 
well-matched years should also be taken into consideration. 
 
 
There is a lack of studies evaluating the effectiveness of giving prophylaxis to HCWs in LTCFs. The 
CDC recommends consideration of prophylaxis for unvaccinated HCWs caring for people at high-risk 
of complications, and for all employees regardless of vaccination status if an outbreak is due to a 
strain which is poorly matched to the current vaccine strains3. In order to protect vulnerable people, 
ECDC also recommends consideration of prophylaxis for HCWs, particularly when low IVE is expected 
due to strain mismatch120. As IVE is lower in those who are elderly and frail than in younger healthy 
people, it would seem prudent to have a low threshold for offering prophylaxis to those caring for 
them, and particularly so if chains of transmission from a resident to staff are described; or from a 
resident to staff to resident. 
Key points 2: 
 Early recognition of a potential outbreak is important to facilitate timely antiviral 
treatment, prophylaxis and instigation of IPC measures (prior to virological 
confirmation if appropriate). 
 Rapid point-of care tests may be useful but negative tests do not exclude a diagnosis of 
influenza. 
 Antiviral treatment of symptomatic residents is recommended to be started 
immediately given their high risk of complications. 
 For asymptomatic residents the decision to give antiviral prophylaxis should be made 
on an individual basis using clinical judgement and risk of exposure, but as influenza 
vaccine is considered less effective in the elderly, the threshold for offering antiviral 
prophylaxis to all residents should be low. 
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Conclusion 
Seasonal influenza infection outbreaks are a significant problem in LTCFs both in terms of morbidity 
and mortality for individuals as well as putting additional strain on already overburdened health 
services.  With an increasingly elderly population, demand for LTCF services will likely increase over 
the coming years. Many basic and clinical questions remain unanswered about the transmission, 
prevention and treatment of influenza in these institutions and further evidence is needed to 
determine which interventions, or combination of interventions and hygiene practices are most 
efficacious in these settings. Although vaccination for residents and staff forms the cornerstone of 
preventive influenza policy in LTCFs, and vaccine coverage is high among residents in some 
countries, currently available vaccines are less effective in older people and those with co-
morbidities. Vaccination coverage among HCWs caring for residents of LTCFs is generally much lower 
than for those in other priority groups and efforts are required to improve this to protect the 
vulnerable, the individual HCW and the workforce. Although further studies of the efficacy of 
antiviral treatment and prophylaxis in LTCF setting are required, available data suggest that antivirals 
should be used early during the course of infection for treatment of residents and considered for 
prophylaxis during suspected or confirmed influenza outbreaks to reduce secondary transmission. 
The prevention and control of influenza in LTCFs requires a multi-faceted approach; vaccination and 
antiviral policies form an important part of this, but strong managerial leadership, outbreak 
planning, and a well-trained, educated and engaged workforce are pivotal to the successful 
implementation of infection prevention and control policies.  
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